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Abstract Glomerular filtration rate (GFR) was evaluated
in 32 Wilms’ tumour survivors (WTs) in a cross-sectional
study using 99 Tc-diethylene triamine pentaacetic acid
(99 Tc-DTPA) clearance, the Schwartz formula, the new
Schwartz equation for chronic kidney disease (CKD),
cystatin C serum concentration and the Filler formula.
Kidney damage was established by beta-2-microglobulin
(B-2-M) and albumin urine excretion, urine sediment and
ultrasound examination. Blood pressure was measured. No
differences were found between the mean GFR in 99 Tc-
DTPA and the new Schwartz equation for CKD (91.8±11.3
vs. 94.3±10.2 ml/min/1.73 m
2 [p=0.55] respectively). No
differences were observed between estimated glomerular
filtration rate (eGFR) using the Schwartz formula and the
Filler formula either (122.3±19.9 vs. 129.8±23.9 ml/min/
1.73 m
2 [p=0.28] respectively). Increased urine albumin and
B-2-M excretion, which are signs of kidney damage, were
found in 7 (22%) and 3 (9.4%) WTs respectively.
Ultrasound signs of kidney damage were found in 14
patients (43%). Five patients (15.6%) had more than one
sign of kidney damage. Eighteen individuals (56.25%)
had CKD stage I (10 with signs of kidney damage;
8 without). Fourteen individuals (43.75%) had CKD
stage II (6 with signs of kidney damage; 8 without). The
new Schwartz equation for CKD better estimated GFR in
comparison to the Schwartz formula and the Filler
formula. Furthermore, the WT survivors had signs of
kidney damage despite the fact that GFR was not
decreased below 90 ml/min/1.73 m
2 with 99 Tc- DTPA.
Keywords 99 Tc-DTPA.eGFR formulas.Cystatin C.
CKD.Wilms’ tumour survivors
Introduction
Wilms’ tumour is the most frequently diagnosed tumour in
the kidneys of children [1]. It represents approximately 7%
of all malignancy in children [2]. Currently, the treatment of
Wilms’ tumour is successful in approximately 90% of
cases, and the treatment utilises a combination of induction
chemotherapy, nephrectomy, postoperative chemotherapy
and in some cases radiation therapy [2, 3]. The quality of
life of the patient depends on the potential long-term side
effects of the treatment, such as the impairment of function
of a single kidney.
All treatments may have a potential long-term influ-
ence on the function of solitary kidneys in Wilms’
tumour survivors. According to Daw et al., the most
severe reduction in glomerular filtration rate (GFR; a
reduction of 32%), measured by 99 Tc-DTPA clearance
occurred after nephrectomy [4]. Chemotherapy consists of
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and is administered in the advanced stages and in high-risk
Wilms’ tumours. This treatment may also cause renal
function to deteriorate [5, 6]. Two courses of ifosfamide,
carboplatin and etoposide (ICE) reduced GFR by 7% and
GFR did not decline after another course [4]. Chemother-
apeutic agents, such as vincristine and actinomycin, are
frequently used in the treatment of nephroblastomas and
do not seem to have nephrotoxic effect. Finally, radiother-
apy has been shown to have an adverse effect on kidney
function. De Graff et al. observed a lower value of GFR
measured by 125 I-iothalamate clearance in Wilms’
tumour survivors who underwent radiation of their
abdomen compared with patients who did not undergo
radiation [7].
Decreasing the number of nephrons causes a compensa-
tory increase in the filtration of the remaining nephrons to
maintain excretory demands. However, hyperfiltration may
lead to progressive glomerular sclerosis and a further
reduction in nephrons [8, 9]. Thus, Wilms’ tumour
survivors are at risk of impairment of renal function in the
years following the treatment. This possible complication
makes early detection of the deterioration of renal function
an important need for Wilms’ tumour patients.
The monitoring of GFR in the outpatient department is
based on equations that may have a bias compared with
the current gold standard, inulin clearance. The National
Kidney Foundation (NKF) recommends the Schwartz
formula to estimate GFR in children [10]. Cystatin C is a
low molecular weight protein that is produced in a constant
amount by all nuclear cells and is eliminated from
circulation by glomerular filtration [11, 12]. Although
the NFK does not recommend this, reports claim that
cystatin C can be used to assess glomerular filtration in
children [13]. In 2003, Filler showed that estimating the
GFR using a formula that reflects the relation between the
cystatin C serum concentration and eGFR is much more
accurate to assess glomerular filtration than the Schwartz
formula [14]. In addition, Schwartz recently published a
new equation to estimate GFR in children with chronic
kidney disease (CKD). The new formula is based on the
serum concentration of creatinine, cystatin C and ureic
nitrogen [15].
The first aim of the current study is to compare the
Schwarz formula, cystatin C serum concentration, the
Filler formula and the new Schwarz equation for children
with CKD with 99 Tc-DTPA clearance in Wilms’ tumour
survivors.
The second aim is to assess the prevalence of CKD in
Wilms’ tumour survivors and use the NKF guidelines to
d e t e c te a r l yk i d n e yd a m a g ei ni n d i v i d u a l sw h od on o t
have a decreased GFR, but may be at risk of declining
GFR [16].
Patients and methods
Patients
Thirty-two Wilms’ tumour survivors followed as outpa-
tients at the Medical University of Gdansk were enrolled in
this cross-sectional study. All participants had undergone
unilateral nephrectomy and had been treated according to
the chemotherapy protocols SIOP 9, SIOP 1992, SIOP
2001 between the years 1987 and 2008 [17].
All patients came for an interview where they were
asked questions regarding past medical history of renal
disease and urinary symptoms. Blood pressure was
measured and the participants donated blood for the
measurement of: serum creatinine, blood urea nitrogen
and cystatin C; urine for microscopy and the determina-
tion of albumin, creatinine and beta2 microglobulin
concentrations. All patients underwent renal ultrasound
i m a g i n ga n dh a dt h e i rG F Rm e a s u r e dw i t ha9 9D T P A
renal isotope study.
Methods
Laboratory tests: assessment of GFR
99 Tc-DTPA clearance was defined as the serum activity of
99 Tc-DTPA at 1 and 3 h following the injection of 99 Tc-
DTPA. Results were calculated using a constant body
surface area of 1.73 m
2.
The Schwartz formula was defined as follows: eGFR
in ml/min/1.73 m
2=k × height of child in cm/serum
creatinine concentration in mg/dl; where the constant k
was defined using published literature values: k=0.55 for
children aged 2–12 or adolescent females and k=0.7 for
adolescent males [18].
The new Schwartz equation for children with CKD
was defined as follows: eGFR=39.2 × (height of child in
m/serum creatinine concentration in mg/dl)
0.516 ×( 1 . 8 /
cystatin C serum concentration)
0.294 × (30/BUN)
0.169 ×
(1.099
male/1
female) × (height of child in m/1.4)
0.188][ 15].
Additionally, serum concentrations of cystatin C were
evaluated and eGFR was presented according to the Filler
formula: logGFR=1,.962+[1.123 × log(1/cystatin C) [14].
Serum cystatin C concentration was assessed using the
nephelometric PENIA method (Dade Behring, Marburg,
Germany). Serum creatinine concentrations were assessed
using the colorimetric-modified Jaffe method (mg/dl).
Blood-ureic nitrogen concentration was assessed using the
enzymatic-modified Talke and Schubert method (mg/dl).
Albumin urine concentrations were assessed using the
immunological method, Multigent, from Abbott Labora-
tories (Wiesbaden, Germany). Increased excretion of
albumin with the urine was evaluated as a concentration
760 Pediatr Nephrol (2011) 26:759–766over 20 mg/L and urine albumin to creatinine ratio
(ACR) over 30 mg/g [19]. B-2-M urine concentration was
evaluated with Quantia β2-microglobulin (BIOKIT, Bar-
celona, Spain) as both a concentration and a urine B-2-M
to creatinine ratio (BCR). The cut-off value for the
increased excretion of B-2-M with urine was over
0.32 mg/dl and 0.04 g/mol for BCR [20]. All individuals
enrolled in the study also had a urine test evaluated and
urine sediment analysed. At the time of evaluation, none of
the children had a urinary tract infection confirmed by urine
samples and an assessment of their blood CRP levels.
Value of GFR assessed as clearance of 99 Tc-DTPA,
ACR, BCR, urine sediment analysis and ultrasound
examination were used for classification of patients into
stages of CKD.
Ultrasound examination
In all individuals enrolled in the study, a solitary kidney was
assessedforultrasoundsigns ofkidney damageasdefinedby
the NKF: nephrocalcinosis, cysts, hydronephrosis, stones,
change in the size of the kidney and scars [21]. In the present
study, hyperechoic rings around kidney pyramids were also
assessed as a sign of kidney damage [22]. Patients were
examined in the prone position. The acoustic windows used
in the ultrasound were the lumbar muscles. Examination
conditions were the same for every patient. All patients were
asked not to drink any fluids 1 h before the examination. All
ultrasound examinations were performed by the same
sonographer (M.K.), using the same equipment (GE Logic
500; GE Medical Systems, Waukesha, WI, USA).
Blood pressure
Blood pressure (BP) was measured in every child in the
study by an auscultatory method that used a standard clinical
sphygmomanometer (Maxi Stabil 3; Speidel and Keller,
Jungingen, Germany) and a stethoscope. This method
followed the guidelines established by The Fourth Report
on the Diagnosis, Evaluation, and Treatment of High Blood
Pressure in Children and Adolescents [23]. Each patient had
their blood pressure measured three times. Mean values of
systolic and diastolic pressure were determined for every
Wilms’ tumour survivor. The results were then compared
with reference values matched accordingly to gender, age
and height.
Statistical analysis
Statistical analysis was performed using the Statistica 8.0 PL
software (Polish version; StatSoft, Tulsa, OK, USA). A
normal distribution of the data was verified using the W
Shapiro–Wilk test. Homoscedasticity was verified using the
Levene test. Inter-group comparisons were performed using
the Student’s t test for independent data. A correlation
analysis was performed using Pearson’s or Spearman’s
methods, depending on the character and distribution of the
correlated data. The level of significance was set to p<0.05.
Ethics committee
This study was approved by the Independent Bioethical
Committee of Scientific Researchers at the Medical
University of Gdansk. Written informed consent was
obtained from the legal guardians of the children.
Results
Patients’ characteristics
Thirty-two patients were enrolled in the current study: 13
girls and 19 boys (Table 1). Seven patients (21.9%) were
treated with nephrotoxic agents, such as carboplatin and
ifosfamide. The characteristics of the 7 individuals who
received potentially nephrotoxic agents is presented in
Table 2. Two of those 7 individuals also received irradiation
to the remnant kidney (Table 2). Twelve individuals (37.5%)
underwent radiation therapy. In 3 cases the remnant kidney
underwent irradiation. Nephrotoxic agents were adminis-
tered in the treatment of 2 of those 3 individuals (Table 2;
patients 6 and 7). One person underwent radiation of the
solitary kidney, but did not receive potentially nephrotoxic
agents (Table 2; patient 8)
Glomerular filtration rate
The mean values and standard deviations of glomerular
filtration rates assessed with the methods described are shown
inTable3. No statistical difference was found between the
mean eGFR assessed with the Schwartz formula and that
assessed with the Filler formula (p=0.26). There was a
Table 1 Characteristics of the patients enrolled in the study
Mean Standard
deviation
Median Range
Age (years) 13 5.4 12.2 3.6–24.3
Time of
follow-up (years)
9.3 5.4 7.75 0.3–20.6
Weight (kg) 43.9 16.8 42.8 21.7–77.4
Height (cm) 152.5 20.7 154 110–184.5
BMI (kg/m
2] 18 3 17.5 13.4–24.4
Age at time of
diagnosis (years)
8.52 5.7 2.9 0.08–11.4
BMI, body mass index
Pediatr Nephrol (2011) 26:759–766 761statistical difference between the GFR assessed with 99
Tc-DTPA clearance and first, the eGFR assessed with the
Schwartz formula (p<0.0001), second, the eGFR assessed
with the Filler formula (p< 0.0001). There was a statistical
difference between the new eGFR equation for children
with CKD and first, the Schwartz formula (p<0.0001),
second, the Filler formula (p<0.0001). There was no
statistical difference between the GFR assessed with 99
Tc-DTPA clearance and the new eGFR equation for children
with CKD (p=0.55). The correlation rate between the GFR
with 99 Tc-DTPA clearance and the eGFR assessed with
first, the Schwartz formula, was 0.33 (p<0.05), second, the
Filler formula, was 0.44 (p<0.05), third, the new equation
for children with CKD was 0.33 (p<0.05) and fourth, the
serum cystatin C concentration, was 0.51 (p<0.05).
According to the method of assessment of eGFR, the
prevalence of patients with decreased GFR below 90 ml/min/
1.73 m
2 differed (Table 4). Four patientsenrolled inthe study
hadserum concentrationsofcystatinCover0.95mg/dl.None
of these patients had a GFR decrease below 60 ml/min/
1.73 m
2.
There were no statistical differences in the mean values
of GFR for 99 Tc-DTPA patients who received nephrotoxic
treatment (n=7; 92.68±8.7 ml/min/1.73 m
2) and those who
did not receive the treatment (n=25; 88.86±18.3 ml/min/
1.73 m
2; p=0.43).
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Table 3 Mean values of GFR and standard deviation (SD) assessed
with different methods and the mean value and the SD of cystatin C
serum concentration
Mean GFR (ml/min/1.73 m
2)S D
GFR 99 Tc-DTPA 94.28 10.24
eGFR Schwartz 122.26 19.92
eGFR new Schwartz
equation for children
with CKD
94.26 10.22
Cystatin C 0.76 0.12
eGFR Filler 129.83 23.89
GFR, glomerular filtration rate; eGFR, estimated glomerular filtration
rate; 99 Tc-DTPA, 99 Tc-diethylene triamine pentaacetic acid; CKD,
chronic kidney disease
Table 4 Number of patients with a decreased GFR
Number of patients with decreased
GFR (<90 ml/min/1.73 m
2);
GFR 99Tc-DTPA 14 (43.8%)
eGFR Schwartz 1 (3.1%)
eGFR new Schwartz equation
for children with CKD
11 (34.4%)
eGFR Filler 0
CKD chronic kidney disease
762 Pediatr Nephrol (2011) 26:759–766Signs of kidney damage
Increased excretion of albumin (albumin to creatinine
ratio>30mg/g)wasobservedin7outof32patients(22%);an
increased urine concentration (>20 mg/L) was observed in 6
patients(19%).ExcretionofB-2-Mwithurinewaselevatedto
over 0.32 mg/dl in 3 patients and to over 0.04 g/mol in 4
patients. There were no abnormalities in the urine sediment.
Five Wilms’ tumour survivors had more than one sign of
kidney damage: 2 patients had increased excretion of albumin
and B-2-M; 2 patients had increased excretion of albumin and
signs of kidney damage in the ultrasound examination; and 1
patient had increased excretion of B-2-M and signs of kidney
damage in ultrasound examination.
Renal ultrasound findings
The signs of kidney damage in the ultrasound examination
were observed in 14 out of 32 patients (43%; Table 5).
Prevalence of CKD in Wilms’ tumour survivors
Eighteen patients were classified as stage I of CKD: solitary
kidney with (10 patients) or without (8 patients) signs of
kidney damage with a value of GFR of over 90 ml/min/
1.73 m
2. Fourteen patients were classified as having stage II
CKD. Among those, 6 patients had markers of kidney
damage (Table 6).
Blood pressure
Arterial hypertension, based on the mean values of systolic
and diastolic blood pressures from three independent
measurements, over the 95th centile was observed in 2
individuals (6.25%). Two people (6.25%) enrolled in the
study had diastolic blood pressure over the 95th centile.
One of them had systolic blood pressure over the 90th
centile. Mean systolic and diastolic blood pressures over the
90th centile were observed in 2 Wilms’ tumour survivors
(6.25%). One person had systolic blood pressure over the
90th centile. None of the individuals enrolled to the study
had been administered antihypertensive drugs.
Discussion
The current study compared the values of GFR measured
with 99 Tc-DTPA clearance, a reference method, with
eGFR evaluated using other methods: the Schwartz
formula, which is the formula recommended by the NKF;
the new Schwartz equation, which is used for children with
CKD; serum cystatin C concentration, which is a low
molecular protein that may become an alternative for
creatinine serum concentration used to detect early glomer-
ular impairment in children; and the Filler formula, which is
a mathematical formula based on cystatin C.
There was no statistical difference between GFR 99 Tc-
DTPA and the new eGFR equation for children with CKD
(p=0.55) in the present study. No difference was observed
in the mean values of GFR for 99 Tc-DTPA of patients who
did and did not receive nephrotoxic treatment (p=0.43).
Among all individuals enrolled in the study, 7 (22%) had
increased albumin urine excretion; 3 (9.3%) presented
increased B-2-M urine excretion and 14 (43%) had signs
of kidney damage on ultrasound examination. The preva-
lence of CKD in the study was as follows: 18 patients were
classified as CKD stage I and 14 as CKD stage II.
The values of 99 Tc-DTPA clearance obtained in this
study were similar to values previously published in the
literature on Wilms’ tumour survivors. In a study by Levitt
et al., 19% of individuals after treatment for nephroblas-
toma had decreased GFR (below 80 ml/min/1.73 m
2)
measured as clearance of 51-chromium diamine tetraacetic
acid (51 Cr-EDTA) [24]. Srinivas et al. did not observe any
decreased GFR in Wilms’ tumour survivors using the 99
Tc-DTPA clearance [25]. The GFR of single kidneys in
individuals after treatment for Wilms’ tumour was mea-
sured with 125 I-iothalamate clearance by De Graaf et al.
The authors noticed that GFR in children who did not
receive radiation therapy on the single kidney had a mean
Table 5 Prevalence of signs of kidney damage in ultrasound
examination
Sign of kidney damage in
ultrasound examination
Number of patients
Hyperechoic rings around renal pyramids 12
Renal scars 3
Echogenicity of renal cortex 5
Urolithiasis 0
Cysts 1
Table 6 Prevalence of CKD in Wilms’ tumour survivors
Number of
patients
CKD stage I GFR>90 ml/min/1.73 m
2
no signs of kidney damage
8
GFR>90 ml/min/1.73 m
2+
signs of kidney damage
10
CKD stage II GFR 60–89 ml/min/1.73 m
2
no signs of kidney damage
8
GFR 60–89 ml/min/1.73 m
2+
signs of kidney damage
6
Pediatr Nephrol (2011) 26:759–766 763GFR of 94.6% of the normal rate and those who received
radiation therapy to their solitary kidney had a mean GFR
of 72.7% of the normal rate [7]. Schell et al. evaluated GFR
in Wilms’ tumour survivors using inulin clearance. The
mean values of GFR were 85 ml/min/1.73 m
2 [26].
According to Chevallier et al., the mean inulin clearance
in Wilms’ tumour survivors was 93 ml/min/1.73 m
2 [27].
In the current study, the eGFR estimated with the Schwartz
formula was significantly higher than the GFR measured with
99 Tc-DTPA. The fact that the Schwartz formula over-
estimates eGFR by approximately 10 ml/min/1.73 m
2 is a
well-known phenomenon [28]. Seikaly et al. reported that
this overestimation can reach even 20 ml/min/1.73 m
2 in
individuals with decreased eGFR [29]. The difference
between inulin clearance and creatinine clearance in Wilms’
tumour survivors was presented by Donckerwolcke and
Coppes: 82.3 ml/min/1.73 m
2 and 176.2 ml/min/1.73 m
2
respectively [30]. Thus, detection of individuals with eGFR
between 90 and 60 ml/min/1.73 m
2 with the Schwartz
formula is difficult. Mattman et al. underlined the need for a
derivation of the Schwarz formulas in a local laboratory
setting to avoid bias [31].
A marker for CDK, which may be more sensitive to the
detection of early renal impairment, is cystatin C, although it
is not recommended by the NKF to evaluate renal function
[28]. According to Kazama et al., a cystatin C serum
concentration over 0.98 mg/dl has a sensitivity of 88.5% and
a specificity of 95.2% for detecting GFR below 80 ml/min/
1.73 m
2 [32]. Our study presented a higher correlation
rate between 99 Tc-DTPA and serum concentration of
cystatin C than between 99Tc-DTPA and eGFR Schwartz
formula: −0.51 vs. 0.33 respectively. The value of cystatin C
serum concentration that should act as the cut-off value to
avoid impairment of the filtration rate is still unknown.
Fischbach et al. proposed a value of 0.95 mg/dl as a cut-off
value and this is the highest value published in the literature
[13]. According to Stefanowicz et al., 42% of individuals
after treatment of Wilms’ tumour had a serum concentration
of cystatin C that was elevated to over 0.95 mg/dl [33].
Filler and Lapage proposed a mathematical formula that
expresses the relation between cystatin C serum concen-
trations and eGFR [14]. Authors reported that agreement
between 99 Tc-DTPA and eGFR by the Schwartz formula
showed a bias of 10.8%. Agreement between 99 Tc-DTPA
and the Filler formula presents bias of only 0.3% [14, 18].
Inourstudy,wedidnotobserveadifferenceinmeanvaluesof
eGFR between the Schwartz and Filler formulas, and we
observed a statistical difference between eGFR by the Filler
formula and 99 Tc-DTPA clearance. The correlation between
the two methods was 0.44. Our study reported that the Filler
formula is not superior over the Schwartz formula in the
detection of early renal impairment in Wilms’ tumour
survivors. In the current study, cystatin C serum concentration
(r=0.51) correlated better with 99 Tc-DTPA than with eGFR
assessed with the Filler formula (r=0.44). Also, cystatin C
serum concentration over 0.95 mg/dl determines decreased
GFR in 99Tc-DTPA in more individuals than eGFR with the
Filler formula.
Recently, Schwartz et al. published a new equation to
estimate GFR in children. The formula is based on the
serum concentration of creatinine, BUN and cystatin C
[15]. The equation was established from 349 children with
CKD and a mean GFR of 41.2 ml/min/1.73 m
2 measured as
iohexol plasma disappearance. The formula yielded an
eGFR of 87.7% within an iohexol GFR of 30% [15]. In the
current study, the new equation is found to have a better
detection of CKD in Wilms’ tumour survivors than both the
Schwarz and the Filler formulas. This is despite the fact that
individuals enrolled in the study had higher values of GFR
than those in the study by Filler and Lepage [14].
Currently, in light of the definition of chronic kidney
disease for individuals with a risk of deterioration of kidney
function, it is essential not only to objectively assess GFR,
but also to establish of the presence of markers of kidney
damage. Markers of kidney damage are structural or
functional abnormalities that may lead to decreased GFR
[34]. The NKF recommends evaluation of proteinuria as a
marker of kidney damage in children and albuminuria in
adults [35]. In adults, kidney damage is frequently an
outcome of glomerular diseases that are due to hypertension
or diabetes. In children, kidney damage is an outcome of
congenital tubular abnormalities, which is why proteinuria
is more sensitive [35]. The deterioration of kidney function
in Wilms’ tumour survivors is due to glomerular damage
caused by hyperfiltration [8, 9]. Thus, individuals enrolled
in the current study had their albumin to creatinine ratio
assessed. The value of the ratio was increased in 22% of the
individuals enrolled in the current study. The increased
excretion of albumin with urine in Wilms’ tumour survivors
has been assessed in previously published studies. In
studies by Di Tullio et al., Cioce et al., Levitt et al. and
Srinivas et al., the prevalence of increased albumin
excretion with urine was 32%, 37%, 9% and 84%
respectively [24, 25, 36, 37].
Other laboratory markers of kidney damage included
abnormal urine sediment. There was no abnormality in the
urine sediment in the group analysed. Increased excretion
of B-2-M was noticed in three individuals. All of them
presented other signs of kidney damage, so the presence of
B-2-M did not influence the prevalence of CKD in the
study’s population. Individuals with increased excretion of
B-2-M were observed in a similar manner to people who
obtained nephrotoxic treatment.
Structural abnormalities in kidneys can be detected in
imaging studies. The NKF recommends using ultrasound,
intravenous pyelography, computed tomography, magnetic
764 Pediatr Nephrol (2011) 26:759–766resonance imaging, or nuclear scans. Ultrasound is an
imaging test that is the most frequently performed in
Wilms’ tumour survivors. In our study, we exceeded the
ultrasound signs of kidney disease compared with that
presented by the NKF [21]. Additionally, we evaluated the
presence of hyperechoic rings around renal pyramids,
which is an outcome of tubular dysfunctions [22, 38].
According to our knowledge in previously presented
studies, structural abnormalities in ultrasound examination
were not considered.
Blood pressure is not an integral part of the definition of
CKD, although it may act as a clinical marker of kidney
diseases [10]. Presence of hypertension in individuals with
CKD may increase the risk of cardiovascular complica-
tions. Arterial hypertension (systolic and diastolic blood
pressure above the 95th centile) was diagnosed in two
individuals (6.25%). Another two individuals (6.25%) had
systolic and diastolic blood pressure above the 90th centile,
but below the 95th centile. Prevalence of hypertension in
the present study is lower than in previously published
studies—11–29% of the total cases [23, 39].
The prevalence of CKD in Wilms’ tumour survivors has
not yet been analysed. All patients who underwent treatment
for Wilms’tumourcanbeconsideredtohaveCKD,since they
lack a kidney. In the current study, 18 (56.25%) individuals
had stage I CKD: 10 of them had signs of kidney damage; in
8 cases those signs were not observed. Fourteen Wilms’
tumour survivors (43.75%) were classified as having stage II
CKD. Six of them had signs of kidney damage. In 8 cases
thosesignswerenotobserved(Table6). The main therapeutic
goal in an individual with stage I CKD is to treat the
comorbid conditions and reduce the risk of cardiovascular
diseases. In stage II of CKD, the goal is to estimate the
progression of CKD.
To appropriately test for CKD, prospective follow-up
must be planned to assess the risk of deterioration of
function of the single kidney in Wilms’ tumour survivors
with and without markers of kidney damage.
To conclude the study we claim that the evaluation of a
single kidney in Wilms’ tumour survivors should consist of
the assessment of eGFR, albumin and B-2-M urine
excretion, urine sediment analysis and ultrasound examina-
tion. A new equation (the new Schwartz formula) for the
estimation of eGFR in children with CKD was found to
better predict eGFR more accurately than the Schwartz
formula and the Filler formula in comparison to 99 Tc-
DTPA clearance. Thus, the new Schwartz formula ought to
be considered the method of GFR estimation to be used in
everyday practice.
It needs to be underlined that although GFR did not
decrease below 90 ml/min/1.73 m
2 with 99 Tc-DTPA,
Wilms’ tumour survivors still displayed signs of kidney
damage in laboratory and ultrasound examinations. It is
essential to additionally evaluate the presence of albumin,
B-2-M urine excretion and ultrasound signs of kidney
damage that may indicate early renal impairment.
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